MSD Signs a Two-Year Research Agreement with Almac to Discover DUB Therapeutic Targets for Neurodegenerative Diseases

 MSD Signs a Two-Year Research Agreement with Almac to Discover DUB Therapeutic Targets for Neurodegenerative Diseases

Shots::stosohSthShots:

  • Almac to receive upfront, research funding, development and commercial milestones along with the royalties on sales of products emerging from the collaboration. MSD will be responsible for conducting lead optimization, pre/clinical development and commercialization
  • The collaboration will utilize Almac’s unique Ubi-Plex platform to identify and develop novel inhibitors against specified DUBs and will initially focus on neurodegenerative diseases
  • Almac’s Ubi-Plex platform offers the opportunity to generate novel, innovative candidate drugs targeting multiple therapeutic areas including oncology, viral, inflammatory and metabolic disorders

Click here ­to­ read full press release/ article | Ref: Almac | Image: GMP News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post